Well I wouldn't be too surprised if there is an offering here. So in the very short term maybe it has gotten ahead of itself.
But long term I think it is still a very good buy. If everything goes right they could end up as a major oncology company, and the EGFR news is very intriguing - it significantly increased the potential upside, although this still has to be classed as a speculative opportunity. We should know more by the end of the year.
ARIA was already my biggest position when the stock was under $2 and I still have pretty much all the shares I did then, so it's not inconceivable that I will lighten up a little (but not much) at some point.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.